Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

SESEN BIO, INC.

(SESN)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Sesen Bio Up 33% After Regulatory Updates

10/20/2021 | 01:57pm EST

By Josh Beckerman

Sesen Bio Inc. shares were recently up 33% to $1.34 after it provided updates on U.S. and Europe drug approval steps in securities filings.

Sesen said Tuesday that the Food & Drug Administration granted its request for a Type A meeting to discuss the chemistry, manufacturing and controls issues raised in the FDA's complete response letter for Vicineum.

On Wednesday, Sesen said the European Medicines Agency issued a withdrawal assessment report for the company's Vysyneum application.

"Due to the high concordance between FDA and European Commission approvals, the company believes that the probability of success of future approval in the European Union for Vysyneum increases if FDA approval for Vicineum has already been obtained," the company said.

Sesen shares fell sharply in August when the FDA issued a CRL on its application for Vicineum for treatment of BCG-unresponsive non-muscle invasive bladder cancer.

Write to Josh Beckerman at josh.beckerman@wsj.com

(END) Dow Jones Newswires

10-20-21 1557ET

All news about SESEN BIO, INC.
11/23Sesen Bio Director Jane Pritchett Henderson Transitions to CEO Advisor Role
BU
11/23SESEN BIO, INC. : Change in Directors or Principal Officers, Financial Statements and Exhi..
AQ
11/23Sesen Bio, Inc. Announces Director Jane Pritchett Henderson Transitions to CEO Advisor ..
CI
11/18SESEN BIO, INC. : Regulation FD Disclosure (form 8-K)
AQ
11/08Sesen Bio Reports Third Quarter 2021 Financial Results and Business Update
BU
11/08SESEN BIO, INC. Management's Discussion and Analysis of Financial Condition and Result..
AQ
11/08Earnings Flash (SESN) SESEN BIO Reports Q3 EPS $0.36
MT
11/08Sesen Bio, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended Se..
CI
11/01Sesen Bio 'Pleased' by Oct. 29 FDA Meeting on Lead Product Candidate Rejected in August
DJ
11/01Sesen Bio Reports 'Productive' FDA Meeting After Complete Response Letter for Bladder C..
MT
More news
Analyst Recommendations on SESEN BIO, INC.
More recommendations
Financials (USD)
Sales 2021 6,53 M - -
Net income 2021 -21,0 M - -
Net Debt 2021 - - -
P/E ratio 2021 -9,39x
Yield 2021 -
Capitalization 215 M 215 M -
Capi. / Sales 2021 33,0x
Capi. / Sales 2022 -
Nbr of Employees 27
Free-Float 99,9%
Chart SESEN BIO, INC.
Duration : Period :
Sesen Bio, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends SESEN BIO, INC.
Short TermMid-TermLong Term
TrendsNeutralBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 3
Last Close Price 1,08 $
Average target price 2,25 $
Spread / Average Target 108%
EPS Revisions
Managers and Directors
Thomas R. Cannell President, Chief Executive Officer & Director
Monica Forbes Chief Financial Officer & Treasurer
Jay S. Duker Chairman
Glen C. MacDonald Chief Technology Officer
Jeannick Cizeau Head of Research
Sector and Competitors
1st jan.Capi. (M$)
SESEN BIO, INC.-20.00%215
GILEAD SCIENCES, INC.20.61%88 146
BIONTECH SE326.89%84 049
REGENERON PHARMACEUTICALS33.17%67 266
WUXI APPTEC CO., LTD.24.40%64 416
VERTEX PHARMACEUTICALS-22.32%46 678